News & Updates

Show Multimedia Only
Bladder preservation possible in select MIBC patients
Bladder preservation possible in select MIBC patients
29 Dec 2025
1L osimertinib for EGFRm NSCLC: Who are the long-term responders?
1L osimertinib for EGFRm NSCLC: Who are the long-term responders?
21 Dec 2025 byNatalia Reoutova

A retrospective study by researchers from the Chinese University of Hong Kong has found that patients with EGFR mutation–positive (EGFRm) non-small-cell lung cancer (NSCLC) who had a good performance status (PS) and no brain, liver or bone metastases at diagnosis had lower odds of progression or death at 2 years with osimertinib monotherapy. Furthermore, patients with oligoprogressive disease (OPD) had better outcomes than those with systemic progressive disease (SPD), and local ablative therapy (LAT) was shown to effectively defer switching systemic therapy in patients with OPD.

1L osimertinib for EGFRm NSCLC: Who are the long-term responders?
21 Dec 2025
HPV vaccine uptake remains low in SG despite improved awareness
HPV vaccine uptake remains low in SG despite improved awareness
18 Dec 2025